SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?


To: 5,17,37,5,101,... who wrote (274)2/12/1999 2:07:00 PM
From: CPAMarty  Respond to of 2515
 
.......simple as that. I think if all is good at IMCL and no competing drug to worry us, then what is really happening is investors are skeptical of biotech in general and waiting for proof positive.
BINGO, I think you have hit on the reason for the recent price action in this stock. This boat will not leave the dock until the formal announcement and, as another poster put it, by then all the invited guests will be on board. Have been watching this one daily; and, in general, it rises on heavy volume and drifts back on light volume.



To: 5,17,37,5,101,... who wrote (274)2/14/1999 12:58:00 PM
From: JEB  Read Replies (1) | Respond to of 2515
 
The IMCL chart is showing sell indicators:

bigcharts.com

A good buying opportunity is coming up soon but I would wait until it has bottomed maybe around 9 short term. If it breaks through that then we could go as low as 7.

Wild card - If the company see's fit to release formal news of the FDA approval then we could see 13 7/8 again...we shall see!

Good trading,
JEB



To: 5,17,37,5,101,... who wrote (274)2/15/1999 12:12:00 PM
From: StockMiser  Read Replies (2) | Respond to of 2515
 
MM's can stall and stop upward momentum at any time, unless there is major buying pressure from elsewhere, and even then can still manipulate price because of the number of shares they control. They merely drop the ask with a small number of shares, which spooks short-term and daytraders into selling below MM's ask or at the bid. This process creates downward momentum, and the MM moves to the now lower BID and picks up shares cheap. This happens about 1000 times every day with many many stocks. MM's also don't have to report accurate lot sizes...I see 100 volume bids by MM's all the time pick up 10-20-30,000 shares over time. The reverse is true when MM's want to dump shares...they create "artificial" upward momentum and sell into the momentum traders. Unless you watch the action of an MM on a particular stock, its very difficult to determine if they have a client that wants to buy or sell.

In relation to biotech stocks, they got it easy. During "news pops" they are happy to accomodate upward momentum players, and either sell shares outright, or short at the top. Since biotechs cool off very quickly, and have long "quiet" periods between news, they can cover their shorts slowly over time or re-establish a long position, forcing the price lower to get shares cheaper. This is how they make a living :-)

Oh...more to the point. I just started looking closely at IMCL. They look like a good hold if you get in below 10. If the results of Phase III look good, they can apply for fast track approval usually about 1-2 years into Phase III (assuming material results), and actually market the product prior to completion of Phase III. I also noticed an anti-angiogensis product in pre-clinical. IMCL has the main elements I look for in a speculative biotech - (1) products in phase III, (2) products with large markets, (3) partnerships with larger bio's, (4) other good products in the pipe, (5) well respected in the scientific community.

Does anyone know the survivability stats for C225?

Thanks!
SM